PMID- 11180764
OWN - NLM
STAT- MEDLINE
DCOM- 20010927
LR  - 20220317
IS  - 1340-6868 (Print)
IS  - 1340-6868 (Linking)
VI  - 8
IP  - 1
DP  - 2001
TI  - Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in 
      human breast cancer.
PG  - 38-44
AB  - Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of 
      human breast cancers and has been shown to be accompanied by the overexpression 
      of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of 
      the first genetic alterations to be used clinically as a prognostic indicator, a 
      predictive factor of response to doxorubicin (adriamycin) chemotherapy, and a 
      test of patient eligibility for therapy with trastuzumab, a humanized 
      anti-c-erbB-2 antibody. There are two types of tests to detect c-erbB-2 
      amplification/overexpression: immunohistochemistry and fluorescence in situ 
      hybridization (FISH). Accurate identification of cases with c-erbB-2 
      amplification/overexpression requires an optimized combination of 
      immunohistochemical and FISH tests.
FAU - Tsuda H, H
AU  - Tsuda H H
AD  - Pathology Division, National Cancer Center Research Institute, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Japan
TA  - Breast Cancer
JT  - Breast cancer (Tokyo, Japan)
JID - 100888201
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/*diagnosis/genetics/metabolism
MH  - Female
MH  - *Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Proto-Oncogene Mas
MH  - Receptor, ErbB-2/*metabolism
MH  - Survival Rate
RF  - 46
EDAT- 2001/02/17 11:00
MHDA- 2001/09/28 10:01
CRDT- 2001/02/17 11:00
PHST- 2001/02/17 11:00 [pubmed]
PHST- 2001/09/28 10:01 [medline]
PHST- 2001/02/17 11:00 [entrez]
AID - 10.1007/BF02967476 [doi]
PST - ppublish
SO  - Breast Cancer. 2001;8(1):38-44. doi: 10.1007/BF02967476.